Posts

Driven by GLP‑1s, Pharma’s Relationship with Consumers Is Starting to Change

on

Trump Administration Indefinitely Delays Medicare Weight-Loss Drug Pilot Program

on

How GLP-1 Weight Loss Compounders Reshaped the Drug Industry

on

Lilly Tops Novo in Weight Loss Again, This Time on the Oral Front

on

Recent Developments in Jiangsu Hengrui Pharmaceuticals: Global Deals and Clinical Leadership

on

Friday Five: Sanofi and Roche Face Headwinds Amid US Pricing Pressures and 2026 Drug Pipeline Shifts

on

Teva Launches First Generic GLP-1 for Weight Loss Amid Ongoing Market Developments

on

Structure Therapeutics’ oral obesity drug shows competitive early data vs Novo and Lilly

on

Eli Lilly Becomes First Drugmaker to Reach $1 Trillion Valuation

on

From Weight Loss to Hair Loss: The Search for the Next Blockbuster – Recent Developments and News (2024-2025)

on

Weight-loss Drugs Lead Latest Batch of FDA Priority Voucher Recipients

on

Trump Announces Sweeping Cost Cuts on Lilly and Novo Weight Loss Drugs in Exchange for Medicare Coverage

on

Eli Lilly Blows Past Revenue Benchmarks, Again Raises Full-Year Outlook

on

Novo Nordisk Launches Surprise Bid for Metsera, Topping Pfizer Offer; Pfizer Alleges Move May Violate Antitrust Law

on

Weight-loss drug stocks drop after Trump pledges major price cuts

on

Skye Bioscience’s Nimacimab Fails Mid-Stage Obesity Trial, Stock Plummets

on

Roche’s Top Three Ambition in Obesity Not Dependent on a Single Megablockbuster

on

FDA Scrutinizes Telehealth Firms Like Hims for GLP-1 Drug Advertising Practices

on

Novo Nordisk to Cut 9,000 Jobs Globally as New CEO Targets $1.3B Savings by 2026

on

Stockpiling Frenzy Prompts Lilly to Suspend UK Mounjaro Supply

on